Naveed Rana, MD
Hematology & Oncology · Indianapolis, INNPI 1609863380
Payments from drug & device makers
Across 117 payments — averaging $472.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mirati Therapeutics, Inc.$38K
- Bristol Myers Squibb$14K
- E.r. Squibb & Sons, L.L.C.$2K
- Novartis$414
- AbbVie$247
- Pfizer$175
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,216100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mirati Therapeutics, Inc. | 2 | $37,514 |
| Bristol Myers Squibb | 13 | $13,609 |
| E.r. Squibb & Sons, L.L.C. | 8 | $2,249 |
| Novartis | 23 | $414 |
| AbbVie(2 entities) | 8 | $247 |
| Pfizer | 11 | $175 |
| Johnson & Johnson | 4 | $124 |
| Gilead(2 entities) | 7 | $122 |
| AstraZeneca | 5 | $90 |
| Merck | 4 | $89 |
| Exelixis Inc. | 4 | $70 |
| Adaptive Biotechnologies Corporation | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $57 |
| GSK | 3 | $50 |
| Astellas Pharma US Inc | 2 | $47 |
| Menarini Silicon Biosystems, Inc. | 1 | $41 |
| Sanofi | 1 | $35 |
| Lilly USA, LLC | 2 | $35 |
| Seagen Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| ADC Therapeutics America, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| Genmab U.S., Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Legend Biotech USA Inc. | 1 | $18 |
| Acrotech Biopharma Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Tempus AI, Inc | 1 | $15 |
| Amgen | 1 | $14 |
| Iovance Biotherapeutics, Inc. | 1 | $13 |
How this compares
$55,304 in reported general payments places this provider in the 70th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 92 | $1,822,811 |
| JakafiRuxolitinib Phosphate | 63 | $899,558 |
| PomalystPomalidomide | 35 | $681,399 |
| CabometyxCabozantinib S-Malate | 23 | $640,008 |
| ImbruvicaIbrutinib | 21 | $357,504 |
| VenclextaVenetoclax | 20 | $303,986 |
| PromactaEltrombopag Olamine | 16 | $292,824 |
| LynparzaOlaparib | 13 | $240,606 |
| EliquisApixaban | 265 | $195,603 |
| JaypircaPirtobrutinib | 16 | $117,417 |
| Abiraterone Acetate | 34 | $54,341 |
| XareltoRivaroxaban | 42 | $38,507 |
| Anastrozole | 204 | $3,330 |
| Dexamethasone | 115 | $2,087 |
| Tamoxifen Citrate | 47 | $1,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $13,609 | $1,822,81192 claims |
| Incyte CorporationJakafi | $22 | $899,55863 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,249 | $681,39935 claims |
| Exelixis Inc.Cabometyx | $70 | $640,00823 claims |
| AbbVieVenclexta | $247 | $303,98620 claims |
| NovartisPromacta | $414 | $292,82416 claims |
| AstraZenecaLynparza | $90 | $240,60613 claims |
| PfizerEliquis | $175 | $195,603265 claims |
| Lilly USA, LLCJaypirca | $35 | $117,41716 claims |
| Johnson & JohnsonXarelto | $124 | $38,50742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Attaya SuvannasankhaIndianapolis$8.2M
- Shadia JalalIndianapolis$4.6M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
- Anand TandraIndianapolis$2.2M
- Brian MulherinIndianapolis$2.2M
- Kathy MillerIndianapolis$1.9M
- Anita TurkIndianapolis$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.